Ziprasidone Mesylate Patent Expiration

Ziprasidone Mesylate is Used for managing symptoms of bipolar disorder, neuroleptic diseases, and psychosis. It was first introduced by Viatris Specialty Llc in its drug Geodon on Jun 21, 2002. 3 different companies have introduced drugs containing Ziprasidone Mesylate.


Ziprasidone Mesylate Patents

Given below is the list of patents protecting Ziprasidone Mesylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Geodon US6110918 Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist Mar 26, 2017

(Expired)

Viatris
Geodon US6232304 Inclusion complexes of aryl-heterocyclic salts Apr 01, 2017

(Expired)

Viatris
Geodon US6399777 Inclusion complexes of aryl-heterocyclic salts Apr 01, 2017

(Expired)

Viatris



Ziprasidone Mesylate Generics

Several generic applications have been filed for Ziprasidone Mesylate. The first generic version for Ziprasidone Mesylate was by Gland Pharma Ltd and was approved on Dec 26, 2019. And the latest generic version is by Msn Laboratories Private Ltd and was approved on Sep 15, 2022.

Given below is the list of companies who have filed for Ziprasidone Mesylate generic.


1. GLAND PHARMA LTD

Gland Pharma Ltd has filed for 1 generic for Ziprasidone Mesylate. Given below are the details of the strengths of this generic introduced by Gland Pharma Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 20MG BASE/VIAL powder Prescription INTRAMUSCULAR AP Dec 26, 2019


2. MSN

Msn Laboratories Private Ltd has filed for 1 generic for Ziprasidone Mesylate. Given below are the details of the strengths of this generic introduced by Msn.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 20MG BASE/VIAL powder Prescription INTRAMUSCULAR AP Sep 15, 2022